Alaunos Therapeutics Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

TCRT$1.67-4.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ALAUNOS THERAPEUTICS, INC.
Date: April 1, 2024	By:	/s/ Dale Curtis Hogue, Jr.
		Dale Curtis Hogue, Jr.
		Interim Chief Executive Officer and Director
		(Principal Executive Officer and Principal Financial Officer)
Date: April 1, 2024	By:	/s/ Ferdinand Groenewald
		Ferdinand Groenewald
		Vice President, Finance
		(Principal Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ Dale Curtis Hogue, Jr.
Signature	Title	Date
Dale Curtis Hogue, Jr.	Interim Chief Executive Officer and Director (Principal Executive Officer and Principal Financial Officer)	April 1, 2024
/s/ Ferdinand Groenewald
Ferdinand Groenewald	Vice President, Finance (Principal Accounting Officer)	April 1, 2024
/s/ Robert Hofmeister
Robert Hofmeister	Director	April 1, 2024
/s/ Robert W. Postma
Robert W. Postma	Director	April 1, 2024
/s/ Jaime Vieser
Jaime Vieser	Director	April 1, 2024
/s/ Holger Weis
Holger Weis	Director	April 1, 2024

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.